Wenqi Jiang
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 4
- Cancer Immunotherapy and Biomarkers 4
- Pancreatic and Hepatic Oncology Research 3
- Cancer-related Molecular Pathways 3
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies 5
- Hepatology top 5%
- Pharmacology top 2%
-
- Lymphoma Diagnosis and Treatment 5
-
- Lung Cancer Treatments and Mutations 4
-
- Hepatitis B Virus Studies 3
Wenqi Jiang
42 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 118
- Oncology 759
- Otorhinolaryngology 117
- Hepatology 210
- Pharmacology 223
- Complementary and alternative medicine 95
Countries citing papers authored by Wenqi Jiang
This map shows the geographic impact of Wenqi Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenqi Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenqi Jiang more than expected).
Fields of papers citing papers by Wenqi Jiang
This network shows the impact of papers produced by Wenqi Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenqi Jiang. The network helps show where Wenqi Jiang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wenqi Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 12 | |
| 6 | 2020 | 1 | |
| 7 | 2020 | 18 | |
| 8 | 2017 | 43 | |
| 9 | 2017 | 38 | |
| 10 | 2016 | 6 | |
| 11 | 2016 | 9 | |
| 12 | 2014 | 1 | |
| 13 | 2013 | 49 | |
| 14 | 2013 | 3 | |
| 15 | 2012 | 5 | |
| 16 | Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy | 2009 | 4 |
| 17 | 2007 | 38 | |
| 18 | 2006 | 87 | |
| 19 | [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma]. | 2003 | 5 |
| 20 | 2003 | 313 |
About Wenqi Jiang
Wenqi Jiang is a scholar working on Otorhinolaryngology, Oncology and Hepatology, having authored 43 papers that have together received 1.6k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Cancer-related Molecular Pathways (3 papers) and Hepatitis B Virus Studies (3 papers). The work is most often cited by research in Oncology (759 citations), Otorhinolaryngology (117 citations) and Hepatology (210 citations). Wenqi Jiang has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include James W. Paxton, Anlong Xu, Min Huang, Yihuai Gao, Shu‐Feng Zhou, Yuchen Cai, You‐Jian He, Huiqiang Huang, Zhihong Lu and Robert B. Diasio. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.